I can't reveal here whether the firm concerned was AstraZeneca or one of its FTSE 100 rivals, but I can say that the five blue chip names featured in this report currently offer an average yield of more than 4%.
But regardless of whether you fancy stashing the cash with AstraZeneca, I strongly urge you to check out THIS BRAND NEW AND EXCLUSIVE REPORT which reveals the seven key steps you need to take to become a stock market millionaire.
The pharmaceutical industry was the focus of intense debate earlier this year owing to potential merger between Pfizer Inc. (NYSE:PFE) and AstraZeneca plc (ADR) (NYSE:AZN). With the six month cooling period coming to its close, the question that looms ...
Respected fund manager Neil Woodford has come out to praise the potential of AstraZeneca (LSE: AZN) (NYSE: AZN.US) this morning, after the company updated investors on its progress over the past few months.